IP Library Patent Application 12589680
Patent Application
App. No. 12/589,680

Aqueous compositions containing metronidazole

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/589,680
Abstract

An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.7%. The solution contains a combination of solubility-enhancing agents, one of which is niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed.

Claims (8)

1 . A method for increasing the solubility of metronidazole in an aqueous fluid comprising combining in the aqueous fluid metronidazole, a first metronidazole solubility enhancer, and a second metronidazole solubility enhancer, wherein the concentration of metronidazole that is combined in the aqueous fluid is higher than the saturated dissolved soluble concentration of metronidazole in the aqueous fluid in the absence of the first and/or second solubility enhancers, wherein the concentration of the first solubility enhancer in the aqueous fluid is higher than its saturated dissolved soluble concentration in the aqueous fluid in the absence of the second solubility enhancer, and wherein the second solubility enhancer is niacinamide at a concentration that is sufficient, in combination with the first solubility enhancer, to increase the dissolved concentration of metronidazole in the aqueous fluid above the saturated dissolved concentration of metronidazole in the absence of the first and second solubility enhancer and that is sufficient to increase the solubility of the first solubility enhancer in the aqueous solution above its solubility in the aqueous fluid in the absence of niacinamide.

2 . The method of claim 1 wherein the aqueous fluid is at a temperature of 5 degrees celsius.

3 . The method of claim 2 wherein the dissolved concentration of metronidazole in the aqueous fluid is between 0.7% and 1.0% w/w.

4 . The method of claim 1 wherein the concentration of metronidazole that is dissolved in the aqueous fluid is higher than that which is dissolvable in the aqueous fluid in the absence of either the first or the second solubility enhancers.

5 . The method of claim 1 wherein the first solubility enhancer is betacyclodextrin.

6 . A pharmaceutical composition comprising an aqueous solution comprising an aqueous fluid, metronidazole, a first solubility enhancer, and a second solubility enhancer which is niacinamide, wherein the concentration of metronidazole in the aqueous solution is higher than the saturated solubility of metronidazole in the aqueous fluid in the absence of either or both of the first and second solubility enhancers, wherein the concentration of the first solubility enhancer in the aqueous fluid is higher than its saturated solubility in the aqueous solution in the absence of the second solubility enhancer, and wherein the concentration of the second solubility enhancer is sufficient to increase the solubility of the first solubility enhancer in the aqueous fluid above its saturated solubility in the absence of the second solubility enhancer.

7 . The pharmaceutical composition of claim 5 which is at a temperature of 5 degrees celsius.

8 . The pharmaceutical composition of claim 5 wherein the first solubility enhancer is betacyclodextrin.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.; ATON PHARMA, INC.
Reel/Frame 025950/0048 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →